

Committee on Energy and Commerce

U.S. House of Representatives

Witness Disclosure Requirement - "Truth in Testimony"

Required by House Rule XI, Clause 2(g)

1. Your Name: David B. Hoyt		
2. Are you testifying on behalf of the Federal, or a State or local government entity?	Yes	No X
3. Are you testifying on behalf of an entity that is not a government entity?	Yes X	No
4. Other than yourself, please list which entity or entities you are representing: American College of Surgeons, American College of Surgeons Professional Association, American College of Surgeons Foundation.		
5. Please list any Federal grants or contracts (including subgrants or subcontracts) that you or the entity you represent have received on or after October 1, 2008: See attached schedule.		
6. If your answer to the question in item 3 in this form is "yes," please describe your position or representational capacity with the entity(ies) you are representing: Executive Director, Executive Director, and President, respectively.		
7. If your answer to the question in item 3 is "yes," do any of the entities disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony? American College of Surgeons Professional Association Surgeons PAC; American College of Surgeons East Ontario, LLC; SAGES FLS and Surgeons Asset Management, LLC	Yes X	No
8. If the answer to the question in item 3 is "yes," please list any Federal grants or contracts (including subgrants or subcontracts) that were received by the entities listed under the question in item 4 on or after October 1, 2008, that exceed 10 percent of the revenue of the entities in the year received, including the source and amount of each grant or contract to be listed: See attached schedule.		

Signature: _____

David B. Hoyt

Date: _____

5/5/2011

**American College of Surgeons
Federal Awards Received Since October 1, 2008
Prepared May 3, 2011**

Awarding Agency	Issue Date	Project Period	Award Amount
Centers for Disease Control and Prevention - American Joint Committee on Cancer	8/26/2009	9/30/2009 - 9/29/2013	\$ 1,288,076
USA Med Research Acq Activity	11/10/2009	3/11/2010 - 3/13/2010	\$ 20,000
National Cancer Institute - University of Michigan	12/7/2009	9/1/2008 - 8/31/2010	\$ 68,551
National Cancer Institute - RTI International	2/10/2010	9/15/2009 - 8/14/2011	\$ 87,000
Centers for Disease Control and Prevention - National Trauma Data Bank	8/30/2010	8/30/2010 - 8/29/2011	\$ 63,000
The Centers for Medicare and Medicaid Services (CMS)	9/1/2010	9/1/2010 - 8/31/2011	\$ 95,000
Agency for Healthcare Research and Quality / Department of Health and Human Services	9/17/2010	12/1/2009 - 11/30/2011	\$ 82,500
Department of Health and Human Services - Wake Forest University Health Sciences	12/6/2010	9/1/2010 - 8/31/2011	\$ 233,670
Illinois Surgical Quality Improvement Conference	1/26/2011	02/11/2011 - 01/31/2012	\$ 45,625

Active Support

NIH 5R01 HL76180

Project Title: Hemorrhagic Shock and Pancreatic Enzyme Products

Principal Investigator: David B. Hoyt, M.D.

% Effort: 10%, Total Direct Costs: \$1,200,000

Period of Support: 3/1/2004 – 3/01/2010

NIH 1 U01 HL077908

Project: The UCSD/San Diego Resuscitation Research Center

Co-Principal Investigator: David B. Hoyt, M.D.

% Effort: 25%, Total Direct Costs \$2,384,165

Proposed Period of Support: 9/1/04 – 2010

NIH - University of Washington

Project Title: Hypertonic Modulation of Inflammation Following Injury

Principal Investigator: David B. Hoyt, M.D.

% Effort: 5%; Total Direct Costs: \$588,381

Period of Support: 5/01/2007 – 11/30/2009

(Transferred to UCI, left on as consultant)